Clinical Trial Update: Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1b/2 clinical trial evaluating TTI-101 in combination for metastatic hormone receptor-positive, HER2-negative breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TTI-101

Snippet

Sponsor: Tvardi Therapeutics, Incorporated | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED